Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Melliuts, Type 2

Interventions

OTHER: Placebo
DRUG: 25 mg PF-05231023
DRUG: 50 mg PF-05231023
DRUG: 100 mg PF-05231023
DRUG: 150 mg PF-05231023

Sponsor

Pfizer